EBS

Emergent BioSolutions Inc. - Q1 2007 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2007. Emergent BioSolutions Inc. is a biopharmaceutical company operating in two segments: Biodefense (centered on BioThrax, an FDA-approved anthrax vaccine) and Commercial (development of vaccines for infectious diseases). The company's primary customers are the U.S. Department of Defense (DoD) and the U.S. Department of Health and Human Services (HHS), which accounted for 96% of total revenues in the quarter.

Key Financial Metrics

Note: Debt figures represent the sum of current and long-term indebtedness. Q1 2007 debt decreased due to the repayment of $8.9 million on a revolving line of credit.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 116% to $26.4 million, driven by a 125% increase in BioThrax doses delivered. Product sales rose to $25.4 million (from $12.2 million), and contract/grant revenues increased to $1.0 million (from $27,000) due to the Sanofi Pasteur collaboration.
• Profitability Improvement: Net loss narrowed by 42% to $2.7 million. The loss from operations improved from $(9.4) million to $(5.8) million.
• Expense Increases:
  • R&D Expenses: Increased 73% to $15.6 million, reflecting expanded biodefense programs (anthrax immune globulin, botulinum vaccine) and commercial clinical trials (typhoid, hepatitis B).
  • SG&A Expenses: Increased 15% to $11.2 million, largely due to costs associated with transitioning to a public company.
• Cash Flow Turnaround: Operating cash flow swung from a use of $18.2 million in Q1 2006 to a generation of $14.8 million in Q1 2007, primarily due to $39.4 million in collections from DoD and HHS.
• Capital Investment: Investing cash outflows surged to $16.5 million, primarily for the construction of a new 50,000 sq. ft. manufacturing facility in Lansing, Michigan.

Guidance, Outlook, and Risks

• Contract Outlook: The DoD and HHS issued Requests for Proposals (RFPs) in May 2007 for additional BioThrax supplies. The DoD RFP covers up to 14.68 million doses through 2011, and the HHS RFP covers up to 18.35 million doses through 2010. No new contracts have been awarded yet.
• Manufacturing Expansion: The company is constructing a new facility in Lansing, Michigan, with an estimated total cost of $75 million ($46 million incurred through March 2007). Large-scale commercial manufacturing is anticipated to begin in 2008, pending FDA approval and validation.
• Liquidity: The company holds $67.6 million in cash. It expects to fund operations through existing cash, BioThrax sales, and committed funding sources (Sanofi Pasteur collaboration, NIAID, Wellcome Trust). Additional debt financing may be sought for facility expansion.
• Key Risks:
  • Government Dependence: Substantially all revenue relies on U.S. government contracts, which are subject to funding appropriations and competitive bidding.
  • Regulatory Approval: Delays in FDA approval for the new manufacturing facility or product candidates (e.g., anthrax immune globulin) could impact growth.
  • Legal Proceedings: Ongoing product liability litigation regarding BioThrax and thimerosal claims, though the company relies on indemnification and statutory protections.
  • Manufacturing Complexity: Reliance on a single contract filler for BioThrax vials (Hollister-Stier) and the complexity of scaling biologics production.

Investor Verification Checklist

• Verify the status of the May 2007 DoD and HHS RFPs and the likelihood of contract awards.
• Confirm the timeline and regulatory status of the new Lansing, Michigan manufacturing facility validation.
• Monitor the outcome of pending BioThrax product liability lawsuits and the status of DoD indemnification claims.
• Assess the progress of the Sanofi Pasteur collaboration and the recognition of deferred revenue.
• Review the company's ability to secure additional financing if BioThrax sales volumes do not meet projections.